GAO Ensured Access To Part D Rebate Data Under House-Passed Bill
Executive Summary
Information on price rebates provided by drug firms to insurers offering Medicare Part D coverage could be accessed by the Government Accountability Office under a bill sponsored by Rep. Henry Waxman, D-Calif., and passed by the House July 29
You may also be interested in...
Republican Strategy To Protect Part D Raises Risks For Pharma
House Oversight and Government Reform Committee Republicans are attempting to deflect criticism of Medicare Part D drug expenditures by redirecting focus back to larger expenditures under Parts A and B
Part D Drug Data Expected To Be Available For Research Dec. 1
CMS is targeting Dec. 1 as the date for opening Medicare Part D drug claims data to both government and independent researchers
One-Quarter Of Part D Drugs Are Rebated To Plans, Rep. Waxman Reports
Twenty-seven percent of the various drug products used by Medicare Part D enrollees are subject to manufacturer rebates that reduce their price, according to a survey of the leading 12 Part D insurance providers